GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » ROE %

Hansoh Pharmaceutical Group Co (HKSE:03692) ROE % : 15.92% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Hansoh Pharmaceutical Group Co's annualized net income for the quarter that ended in Dec. 2023 was HK$4,350 Mil. Hansoh Pharmaceutical Group Co's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was HK$27,328 Mil. Therefore, Hansoh Pharmaceutical Group Co's annualized ROE % for the quarter that ended in Dec. 2023 was 15.92%.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's ROE % or its related term are showing as below:

HKSE:03692' s ROE % Range Over the Past 10 Years
Min: 11.58   Med: 24.96   Max: 53
Current: 13.45

During the past 8 years, Hansoh Pharmaceutical Group Co's highest ROE % was 53.00%. The lowest was 11.58%. And the median was 24.96%.

HKSE:03692's ROE % is ranked better than
78% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.135 vs HKSE:03692: 13.45

Hansoh Pharmaceutical Group Co ROE % Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co ROE % Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial 32.86 17.06 14.53 11.58 13.40

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.78 12.35 11.47 10.90 15.92

Competitive Comparison of Hansoh Pharmaceutical Group Co's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's ROE % distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's ROE % falls into.



Hansoh Pharmaceutical Group Co ROE % Calculation

Hansoh Pharmaceutical Group Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=3584.864/( (25290.176+28213.778)/ 2 )
=3584.864/26751.977
=13.40 %

Hansoh Pharmaceutical Group Co's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=4350.298/( (26442.832+28213.778)/ 2 )
=4350.298/27328.305
=15.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Hansoh Pharmaceutical Group Co  (HKSE:03692) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=4350.298/27328.305
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(4350.298 / 12234.112)*(12234.112 / 35537.665)*(35537.665 / 27328.305)
=Net Margin %*Asset Turnover*Equity Multiplier
=35.56 %*0.3443*1.3004
=ROA %*Equity Multiplier
=12.24 %*1.3004
=15.92 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=4350.298/27328.305
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (4350.298 / 4957.6) * (4957.6 / 3838.25) * (3838.25 / 12234.112) * (12234.112 / 35537.665) * (35537.665 / 27328.305)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8775 * 1.2916 * 31.37 % * 0.3443 * 1.3004
=15.92 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Hansoh Pharmaceutical Group Co ROE % Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines